Frank Ulrich MülLer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frank Ulrich MülLer has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Wilhelm Schmitz
Institute of Pharmacology and Toxicology University of Münster Münster Germany
7 shared publicationsJoachim Neumann
4 shared publicationsGeertje Lewin
Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
3 shared publicationsMarek Matus
3 shared publicationsBeatrix Scholz
Institute of Pharmacology and Toxicology, University of Münster, Germany (B.S., J.S.S., S.H., K.H., F.P., M.D.S., J.S., F.U.M.).
2 shared publicationsBurkhard Riemann
2 shared publications
Latest Publications
- Open Access
Pathophysiological Mechanisms of Cardiac Dysfunction in Transgenic Mice with Viral Myocarditis
Viral myocarditis is pathologically associated with RNA viruses such as coxsackievirus B3 (CVB3), or more recently, with SARS-CoV-2, but despite intensive research, clinically proven treatment is limited. Here, by use of a transgenic mouse strain (TG) containing a CVB3ΔVP0 genome we unravel virus-mediated cardiac pathophysiological processes in vivo and in vitro. Cardiac function, pathologic ECG alterations, calcium homeostasis, intracellular organization and gene expression were significantly altered in transgenic mice. A marked alteration of mitochondrial structure and gene expression indicates mitochondrial impairment potentially contributing to cardiac contractile dysfunction. An extended picture on viral myocarditis emerges that may help to develop new treatment strategies and to counter cardiac failure.
Open AccessPathophysiological Mechanisms of Cardiac Dysfunction in Transgenic Mice with Viral Myocarditis
Viral myocarditis is pathologically associated with RNA viruses such as coxsackievirus B3 (CVB3), or more recently, with SARS-CoV-2, but despite intensive research, clinically proven treatment is limited. Here, by use of a transgenic mouse strain (TG) containing a CVB3ΔVP0 genome we unravel virus-mediated cardiac pathophysiological processes in vivo and in vitro. Cardiac function, pathologic ECG alterations, calcium homeostasis, intracellular organization and gene expression were significantly altered in transgenic mice. A marked alteration of mitochondrial structure and gene expression indicates mitochondrial impairment potentially contributing to cardiac contractile dysfunction. An extended picture on viral myocarditis emerges that may help to develop new treatment strategies and to counter cardiac failure.
- Open Access
- 24 June 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (8) , 10489-10504
Annexin A4 N‐terminal peptide inhibits adenylyl cyclase 5 and limits β‐adrenoceptor‐mediated prolongation of cardiac action potential
Adenylyl cyclases (AC) are essential for the normal and pathophysiological response of many cells. In cardiomyocytes, the predominant AC isoforms are AC5 and AC6. Specific AC5 inhibition was suggested as an option for the treatment of heart failure potentially advantageous over β‐blockers. We previously reported an interaction between the calcium‐binding protein annexin A4 (ANXA4) and AC5 in human embryonic kidney 293 (HEK293) cells and an inhibition of cyclic adenosine monophosphate (cAMP) production in cardiomyocytes. Here, we investigated whether ANXA4 is able to differentiate between AC5 and AC6. In transfected HEK293 cells, ANXA4 specifically co‐immunoprecipitated with AC5 and not with AC6, via its N‐terminal domain. Both ANXA4 and a peptide comprising the ANXA4 N‐terminal sequence (A4N 1‐22 ) decreased the cAMP production in AC5 and not in AC6 expressing cells. In line with ACs inhibition, in myocytes from ANXA4‐deficient mice, β‐adrenoceptor (βAR) stimulation led to a higher increase of the L‐type calcium current (I CaL ) and to an excessive action potential duration (APD) prolongation as compared to wild‐type cardiomyocytes. This enhanced response was reversed in the presence of A4N 1‐22 peptide likely via specific AC5 inhibition. We conclude that via the N‐terminal domain ANXA4 inhibits AC5 not AC6, and that A4N 1‐22 as a specific AC5 inhibitor could serve as a novel therapeutic tool for the treatment of AC5‐linked diseases.
- 24 June 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (8) , 10489-10504
Open AccessAnnexin A4 N‐terminal peptide inhibits adenylyl cyclase 5 and limits β‐adrenoceptor‐mediated prolongation of cardiac action potential
Adenylyl cyclases (AC) are essential for the normal and pathophysiological response of many cells. In cardiomyocytes, the predominant AC isoforms are AC5 and AC6. Specific AC5 inhibition was suggested as an option for the treatment of heart failure potentially advantageous over β‐blockers. We previously reported an interaction between the calcium‐binding protein annexin A4 (ANXA4) and AC5 in human embryonic kidney 293 (HEK293) cells and an inhibition of cyclic adenosine monophosphate (cAMP) production in cardiomyocytes. Here, we investigated whether ANXA4 is able to differentiate between AC5 and AC6. In transfected HEK293 cells, ANXA4 specifically co‐immunoprecipitated with AC5 and not with AC6, via its N‐terminal domain. Both ANXA4 and a peptide comprising the ANXA4 N‐terminal sequence (A4N 1‐22 ) decreased the cAMP production in AC5 and not in AC6 expressing cells. In line with ACs inhibition, in myocytes from ANXA4‐deficient mice, β‐adrenoceptor (βAR) stimulation led to a higher increase of the L‐type calcium current (I CaL ) and to an excessive action potential duration (APD) prolongation as compared to wild‐type cardiomyocytes. This enhanced response was reversed in the presence of A4N 1‐22 peptide likely via specific AC5 inhibition. We conclude that via the N‐terminal domain ANXA4 inhibits AC5 not AC6, and that A4N 1‐22 as a specific AC5 inhibitor could serve as a novel therapeutic tool for the treatment of AC5‐linked diseases.
- Open Access
- 1 March 2019
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 12 (3) , e007071
HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice
Background: A structural, electrical and metabolic atrial remodeling is central in the development of atrial fibrillation (AF) contributing to its initiation and perpetuation. In the heart, HDACs (histone deacetylases) control remodeling associated processes like hypertrophy, fibrosis, and energy metabolism. Here, we analyzed, whether the HDAC class I/IIa inhibitor valproic acid (VPA) is able to attenuate atrial remodeling in CREM-IbΔC-X (cAMP responsive element modulator isoform IbΔC-X) transgenic mice, a mouse model of extensive atrial remodeling with age-dependent progression from spontaneous atrial ectopy to paroxysmal and finally long-lasting AF. Methods: VPA was administered for 7 or 25 weeks to transgenic and control mice. Atria were analyzed macroscopically and using widefield and electron microscopy. Action potentials were recorded from atrial cardiomyocytes using patch-clamp technique. ECG recordings documented the onset of AF. A proteome analysis with consecutive pathway mapping identified VPA-mediated proteomic changes and related pathways. Results: VPA attenuated many components of atrial remodeling that are present in transgenic mice, animal AF models, and human AF. VPA significantly ( P <0.05) reduced atrial dilatation, cardiomyocyte enlargement, atrial fibrosis, and the disorganization of myocyte’s ultrastructure. It significantly reduced the occurrence of atrial thrombi, reversed action potential alterations, and finally delayed the onset of AF by 4 to 8 weeks. Increased histone H4-acetylation in atria from VPA-treated transgenic mice verified effective in vivo HDAC inhibition. Cardiomyocyte-specific genetic inactivation of HDAC2 in transgenic mice attenuated the ultrastructural disorganization of myocytes comparable to VPA. Finally, VPA restrained dysregulation of proteins in transgenic mice that are involved in a multitude of AF relevant pathways like oxidative phosphorylation or RhoA (Ras homolog gene family, member A) signaling and disease functions like cardiac fibrosis and apoptosis of muscle cells. Conclusions: Our results suggest that VPA, clinically available, well-tolerated, and prescribed to many patients for years, has the therapeutic potential to delay the development of atrial remodeling and the onset of AF in patients at risk.
- 1 March 2019
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 12 (3) , e007071
Open AccessHDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice
Background: A structural, electrical and metabolic atrial remodeling is central in the development of atrial fibrillation (AF) contributing to its initiation and perpetuation. In the heart, HDACs (histone deacetylases) control remodeling associated processes like hypertrophy, fibrosis, and energy metabolism. Here, we analyzed, whether the HDAC class I/IIa inhibitor valproic acid (VPA) is able to attenuate atrial remodeling in CREM-IbΔC-X (cAMP responsive element modulator isoform IbΔC-X) transgenic mice, a mouse model of extensive atrial remodeling with age-dependent progression from spontaneous atrial ectopy to paroxysmal and finally long-lasting AF. Methods: VPA was administered for 7 or 25 weeks to transgenic and control mice. Atria were analyzed macroscopically and using widefield and electron microscopy. Action potentials were recorded from atrial cardiomyocytes using patch-clamp technique. ECG recordings documented the onset of AF. A proteome analysis with consecutive pathway mapping identified VPA-mediated proteomic changes and related pathways. Results: VPA attenuated many components of atrial remodeling that are present in transgenic mice, animal AF models, and human AF. VPA significantly ( P <0.05) reduced atrial dilatation, cardiomyocyte enlargement, atrial fibrosis, and the disorganization of myocyte’s ultrastructure. It significantly reduced the occurrence of atrial thrombi, reversed action potential alterations, and finally delayed the onset of AF by 4 to 8 weeks. Increased histone H4-acetylation in atria from VPA-treated transgenic mice verified effective in vivo HDAC inhibition. Cardiomyocyte-specific genetic inactivation of HDAC2 in transgenic mice attenuated the ultrastructural disorganization of myocytes comparable to VPA. Finally, VPA restrained dysregulation of proteins in transgenic mice that are involved in a multitude of AF relevant pathways like oxidative phosphorylation or RhoA (Ras homolog gene family, member A) signaling and disease functions like cardiac fibrosis and apoptosis of muscle cells. Conclusions: Our results suggest that VPA, clinically available, well-tolerated, and prescribed to many patients for years, has the therapeutic potential to delay the development of atrial remodeling and the onset of AF in patients at risk.
- 1 November 2017
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 112, 147
Enhanced Activation of Inflammasome Promotes Atrial Fibrillation
- 1 November 2017
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 112, 147
Enhanced Activation of Inflammasome Promotes Atrial Fibrillation
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 545a
Sodium Valproate Reverses Electrical Remodeling of Atrial Myocytes Isolated from CREM-IbΔC-X Transgenic Mice
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 545a
Sodium Valproate Reverses Electrical Remodeling of Atrial Myocytes Isolated from CREM-IbΔC-X Transgenic Mice
- 6 January 2009
- Published by Wolters Kluwer Health in Circulation
- Vol. 119 (1) , 79-88
Critical Role of Transcription Factor Cyclic AMP Response Element Modulator in β 1 -Adrenoceptor–Mediated Cardiac Dysfunction
Background— Chronic stimulation of the β 1 -adrenoceptor (β 1 AR) plays a crucial role in the pathogenesis of heart failure; however, underlying mechanisms remain to be elucidated. The regulation by transcription factors cAMP response element-binding protein (CREB) and cyclic AMP response element modulator (CREM) represents a fundamental mechanism of cyclic AMP–dependent gene control possibly implicated in β 1 AR-mediated cardiac deterioration. Methods and Results— We studied the role of CREM in β 1 AR-mediated cardiac effects, comparing transgenic mice with heart-directed expression of β 1 AR in the absence and presence of functional CREM. CREM inactivation protected from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in β 1 AR-overexpressing mice. Transcriptome and proteome analysis revealed a set of predicted CREB/CREM target genes including the cardiac ryanodine receptor, tropomyosin 1α, and cardiac α-actin as altered on the mRNA or protein level along with the improved phenotype in CREM-deficient β 1 AR-transgenic hearts. Conclusions— The results imply the regulation of genes by CREM as an important mechanism of β 1 AR-induced cardiac damage in mice.
- 6 January 2009
- Published by Wolters Kluwer Health in Circulation
- Vol. 119 (1) , 79-88
Critical Role of Transcription Factor Cyclic AMP Response Element Modulator in β 1 -Adrenoceptor–Mediated Cardiac Dysfunction
Background— Chronic stimulation of the β 1 -adrenoceptor (β 1 AR) plays a crucial role in the pathogenesis of heart failure; however, underlying mechanisms remain to be elucidated. The regulation by transcription factors cAMP response element-binding protein (CREB) and cyclic AMP response element modulator (CREM) represents a fundamental mechanism of cyclic AMP–dependent gene control possibly implicated in β 1 AR-mediated cardiac deterioration. Methods and Results— We studied the role of CREM in β 1 AR-mediated cardiac effects, comparing transgenic mice with heart-directed expression of β 1 AR in the absence and presence of functional CREM. CREM inactivation protected from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in β 1 AR-overexpressing mice. Transcriptome and proteome analysis revealed a set of predicted CREB/CREM target genes including the cardiac ryanodine receptor, tropomyosin 1α, and cardiac α-actin as altered on the mRNA or protein level along with the improved phenotype in CREM-deficient β 1 AR-transgenic hearts. Conclusions— The results imply the regulation of genes by CREM as an important mechanism of β 1 AR-induced cardiac damage in mice.
- Open Access
- 1 September 2005
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 67 (4) , 575-577
Increased eNOS expression as a compensatory mechanism reducing β-adrenergic responsiveness?
See article by Danson et al.[13](pages 613–623) in this issue.
- 1 September 2005
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 67 (4) , 575-577
Open AccessIncreased eNOS expression as a compensatory mechanism reducing β-adrenergic responsiveness?
See article by Danson et al.[13](pages 613–623) in this issue.
- Open Access
- 1 February 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (8) , 6906-6914
Heart-directed Expression of a Human Cardiac Isoform of cAMP-Response Element Modulator in Transgenic Mice
- 1 February 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (8) , 6906-6914
Open AccessHeart-directed Expression of a Human Cardiac Isoform of cAMP-Response Element Modulator in Transgenic Mice
- 30 January 2004
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 11 (5) , 485-493
Transcription factor AP-2α triggers apoptosis in cardiac myocytes
Idiopathic-dilated cardiomyopathy (IDC) is a common primary myocardial disease of unknown etiology associated with apoptosis, cardiac dilatation, progressive heart failure and increased mortality. An elevation of the transcription factor activator protein 2α (AP-2α) is involved in vertebrate embryonic development and oncogenesis. Here, we show that AP-2α protein is expressed in the human heart and increased in human failing myocardium with IDC. Adenovirus-mediated overexpression of human AP-2α triggered apoptosis and increased mRNA levels of Bcl-2 family members Bax and Bcl-x in rat cardiomyocytes. Immunohistological analysis of human myocardium revealed an increased percentage of AP-2α-positive nuclei in IDC and, interestingly, a colocalization of AP-2α-positive but not -negative cells with a caspase-cleaved fragment of poly(ADP-ribose)polymerase. We suggest AP-2α as a novel cardiac regulator implicated in the activation of apoptosis in IDC.
- 30 January 2004
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 11 (5) , 485-493
Transcription factor AP-2α triggers apoptosis in cardiac myocytes
Idiopathic-dilated cardiomyopathy (IDC) is a common primary myocardial disease of unknown etiology associated with apoptosis, cardiac dilatation, progressive heart failure and increased mortality. An elevation of the transcription factor activator protein 2α (AP-2α) is involved in vertebrate embryonic development and oncogenesis. Here, we show that AP-2α protein is expressed in the human heart and increased in human failing myocardium with IDC. Adenovirus-mediated overexpression of human AP-2α triggered apoptosis and increased mRNA levels of Bcl-2 family members Bax and Bcl-x in rat cardiomyocytes. Immunohistological analysis of human myocardium revealed an increased percentage of AP-2α-positive nuclei in IDC and, interestingly, a colocalization of AP-2α-positive but not -negative cells with a caspase-cleaved fragment of poly(ADP-ribose)polymerase. We suggest AP-2α as a novel cardiac regulator implicated in the activation of apoptosis in IDC.